Antiretroviral Regime for Viral Eradication in Newborns
HIV/AIDS and Infections
About this trial
This is an interventional prevention trial for HIV/AIDS and Infections focused on measuring HIV, antiretroviral treatment, child, testing
Eligibility Criteria
Inclusion Criteria:
- children whose mother with HIV infection
- children whose mother received antiretroviral drugs after 36 gestational weeks or received no drugs before delivery
- live birth
Exclusion Criteria:
- birth weight is less than 2000g
- Apgar score is less than 3 at 1 minute after birth or less than 6 at 5 minute after birth .
Sites / Locations
- Maternal and Child Health Hospital of Guangdong Province
- Maternal and Child Health Hospital of Guangxi Zhuang Autonomous Region
- Maternal and Child Health Hospital of Sichuan Province
- Maternal and Child Health Hospital of Xinjiang Uygur Autonomous Region
- Maternal and Child Health Hospital of Yunan Province
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
Intervention group
Control group
Children will receive antiretroviral treatment (ART) until 6 weeks old after birth. For the first two weeks, Zidovudine (AZT), Lamivudine (3TC) and Nevirapine (NVP) will be used. When the child is 2 weeks old, the regimen will be adjusted and Nevirapine (NVP) will be replaced by Lopinavir/ritonavir (LPV/r). Early infant diagnosis and other relevant testing will be performed to monitor children's HIV infection status. If the child is not infected, ART will be stopped when he/she reaches 6 weeks old. Otherwise, the treatment will be continued.
Children will receive routine prevention of mother-to-child transmission of HIV services. Nevirapine (NVP) or Zidovudine (AZT) will be administrated to them until 6 weeks old after birth. Early infant diagnosis services will be provided when the child is 6 weeks old and repeated when 3 months old. Children with HIV infection will be referred to receive routine HIV infection treatment.